Animalcare Group (ANCR) CMD 2026 summary

Strategic vision, transformation, and growth trajectory

• Targeting GBP 150 million revenue by 2030, with double-digit growth ambitions and sustainable expansion beyond 2030, supported by organic growth, innovation, and M&A.

• Transitioned from a fragmented, highly leveraged business to a focused, growth-oriented platform with reduced debt and a streamlined portfolio by end of 2025.

• Top 10 products now drive organic growth, with owned/licensed products comprising 95% of revenue and gross margin rising from 56% to 65%.

• Randlab acquisition validated the M&A strategy, strengthening the equine segment and exceeding projections.

• Strategic investments in sales force, commercial excellence, and dental channel expansion underpin near-term growth.

Commercial excellence and operational efficiency

• Commercial excellence initiatives, including unified CRM and leadership development, deliver revenue growth 2% higher and earnings growth 5% higher than peers.

• Systemic commercial excellence in Germany led to 35% sales growth for Daxocox and 21% for Plaqtiv+ in 2025.

• Sales force optimization and onboarding initiatives to increase productivity, with incremental EBITDA expected from 2027.

• Manufacturing network consolidation and optimization aim to improve supply reliability, reduce costs, and unlock EBITDA and revenue opportunities, with phased execution through 2029.

• Cash conversion rate from operations targeted at >80%, maintaining a resilient balance sheet and ongoing dividend payments.

Multi-channel and innovation-driven expansion

• Dental franchise expansion into retail and online channels targets a 20% CAGR, leveraging digital marketing and retail partnerships.

• Rights to all channels in Europe for Plaqtiv+ and global rights for Orozyme position the business for significant dental revenue growth by 2030.

• R&D investment increased to 5% of revenue, with a lean, outsourced model and robust governance process to manage risk and accelerate innovation.

• Pipeline includes six assets, such as advanced VHH antibody technology for osteoarthritis and dermatology, targeting dogs, cats, and horses.

• VHH antibody technology acquisition provides entry into a projected $2–3bn companion animal pain market by 2033.